The High-Risk Leukemia/Lymphoma (HRLL) fellowship program at Seattle Children’s Hospital (SCH) provides multidisciplinary care for children with high-risk leukemias and lymphomas who require treatment plans beyond standard chemotherapy, including cellular immunotherapy and Hematopoietic Stem Cell Transplant (HCT). This program has a broad national referral base for novel experimental therapies for children with high-risk leukemias and lymphomas. SCH/Ben Towne Center for Childhood Cancer Research (BTCCR) and Fred Hutch Cancer Center (Fred Hutch) are international leaders in disease biology and early phase biologically-driven pharma, immunotherapy and HCT trials for children with HRL. The HRL fellowship will provide broad multidisciplinary experience in the management of children and adolescents with HRL and exposure to current best active therapies, including HCT, as well as early phase and novel trial therapies in oncology and HCT. |
About the Fellowship
The clinical fellowship position will be available to begin July 1, 2026 but other accommodations may be possible for qualified individuals. The fellowship extends over 12 months, providing exposure to several disciplines. There may be an opportunity to extend the fellowship beyond 12 months for the purpose of research continuation.
Eligibility Criteria
- American Board of Pediatrics certified or eligible in Pediatrics
- American Board of Pediatrics certified or eligible in either Pediatric Hematology/Oncology/BMT in the US or Canada upon matriculation
- Eligible to obtain a Washington state medical licensure
Application Requirements
- Application
- Curriculum Vitae (CV)
- Personal statement
- Three letters of recommendation
- Color photograph